Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update on UX053 in Glycogen Storage Disease Type III (terminated with results posted).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Iii

Drugs mentioned

• UX053

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Glycogen Storage Disease Type III | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-04-16